Skip to main content
Watch Insiders
NKTRHealthcare

Nektar Therapeutics (NKTR) Insider Trading

In the last 90 days, 2 Nektar Therapeutics (NKTR) insiders reported no open-market purchases and 2 sales totaling $43,476. Source: SEC Form 4 filings.

SEC-reported filing activity is provided for research purposes and is not investment advice.

90-day C-suite buyers
0
90-day purchase value
$0.00
Corporate buyers
0
Latest transaction
Aug 18, 2026

Executive filings

Open-market transaction history

Purchase and sale summaries are ordered by the latest reported transaction date.

Open-market insider purchase and sale transactions
DateInsider nameRoleTypeSharesPriceTotal value
Aug 18, 2026Jonathan ZalevskyChief R&D OfficerSale186$71.98$13,388
Aug 18, 2026Howard W RobinPresident & CEOSale418$71.98$30,088
Jun 30, 2026Jonathan ZalevskyChief R&D OfficerSale5,681$70.00$397,670
Jun 17, 2026Howard W RobinPresident & CEOSale20,000$60.75$1,215,056
Jun 15, 2026Jonathan ZalevskyChief R&D OfficerSale5,538$60.71$336,212
May 19, 2026Jonathan ZalevskyChief R&D OfficerSale199$65.51$13,036
May 19, 2026Howard W RobinPresident & CEOSale444$65.51$29,086

Common questions

NKTR insider trading FAQ

Are NKTR insiders buying or selling?
Over the last 90 days, NKTR insiders were net sellers, reporting $0.00 of open-market purchases and $43,476 of sales.
When was the last NKTR insider purchase?
No open-market insider purchase of Nektar Therapeutics stock was reported in the last 90 days.
Where does NKTR insider trading data come from?
Watch Insiders reads the SEC Form 4 filings that Nektar Therapeutics officers, directors, and 10% owners submit to EDGAR, and refreshes this page daily.